Gebro Pharma, held by the Austrian multinational corporation of the same name and a member of CataloniaBio, expects to post 14% growth this year for a total of €72 million in sales. This growth will be possible thanks to the launch of two new drugs, one for pain and one for rheumatology conditions, as well as the company’s increased investment in R&D in 2016. Gebro Pharma, in Austria, made the leap into R&D last year, increasing investment by 20%, which is 7% of the company’s sales in Spain.

You can extend this information to the website of Gebro Pharma.

Photo: The director of Gebro Pharma Sergi Aulinas, and other representatives of the company - © CataloniaBio